Background: The efficacy of conventional chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been controversial as post-remission therapies for adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients. Methods: We retrospectively analyzed 96 adolescent and adult cases of Philadelphia chromosome-negative acute lymphoblastic leukemia to evaluate whether allo-HSCT should be performed after first complete remission (1CR). Results: In total, 34 patients received chemotherapy followed by allo-HSCT (HSCT group) and 62 received chemotherapy alone (chemotherapy group). No significant differences in the event-free survival (EFS) or overall survival were observed between the two groups. In the chemotherapy group, use of pediatric regimens was significantly associated with favorable EFS, while high white blood cell (WBC) count and CD20 positivity were associated with poor outcome. In patients who received pediatric regimens, subsequent allo-HSCT did not influence EFS. In patients who received conventional chemotherapy (adult regimen), subsequent allo-HSCT did not improve EFS. High WBC count and CD20 positivity were also significantly associated with poor EFS in patients who received adult regimens. Patients with low WBC count and absence of CD20 who received adult regimens did not benefit from allo-HSCT. Conclusions: Allo-HSCT may not be required in the pediatric regimen-eligible patients; however, pediatric regimen-ineligible patients with either CD20 positivity or high WBC count should receive allo-HSCT after achieving 1CR.
Introduction
The utility of conventional chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been demonstrated as post-remission therapies for adult Philadelphia chromosomenegative acute lymphoblastic leukemia (Ph-negative ALL) patients. The appropriateness of the post-remission therapy is typically determined by risk stratification; however, the better choice between allo-HSCT and continued conventional chemotherapy in patients who achieve a first complete remission (1CR) remains controversial.
Previous studies found that allo-HSCT was superior to conventional chemotherapy or autologous stem cell transplantation in high-risk patients (1) (2) (3) . On the other hand, the Medical Research Council (MRC)/Eastern Cooperative Oncology Group (ECOG) study and Dutch-Belgian Cooperative Trial Group for Hematology Oncology reported that the superiority of allo-HSCT was restricted to standard-risk patients (4, 5) . Oh et al. performed a matched pair analysis using the Japan Adult Leukemia Study Group (JALSG) cohort and International Bone Marrow Transplant Registry database, and concluded that the superiority of allo-HSCT was observed only in patients under 30 years of age (6) . Recent meta-analyses concluded that allo-HSCT is superior to conventional chemotherapy for ALL patients in 1CR with human leukocyte antigen (HLA)-matched sibling donors in the standard-risk group, but not in the high-risk group (7), or only in younger patients (age < 35 years old) (8) .
Recent studies have demonstrated that pediatric-inspired chemotherapy improves the outcome of adult patients with Ph-negative ALL (9) (10) (11) , while the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2003 and 2005 trials reported no significant difference in relapse-free survival (RFS) between cohorts that did or did not receive allo-HSCT in a time-dependent analysis (12) . In addition, the JALSG ALL 202-U study found no significant difference in disease-free survival between allo-HSCT and chemotherapy cohorts, regardless of cytogenetic risks (13) . However, transplant indication has proved technically challenging in clinical settings due to a lack of HLA-matched donors and intolerance to pediatric-inspired chemotherapy regimens. Therefore, we retrospectively analyzed Ph-negative ALL patients treated in our institutions to compare the prognosis of patients treated with chemotherapy and allo-HSCT to those who received conventional chemotherapy alone after 1CR in clinical settings.
Methods

Patients
The case histories of adolescent and adult patients aged 16-70 years with Ph-negative ALL who achieved 1CR at nine institutions in Chiba prefecture, Japan, between January 2001 and October 2014 were retrospectively analyzed. Patients who did not achieve 1CR or who were not actively treated with chemotherapy were excluded from the analysis.
The primary objective of the study was to compare the event-free survival (EFS) between patients who received allo-HSCT in addition to chemotherapy (HSCT group) and those who received conventional chemotherapy alone (chemotherapy group) as post-remission therapy. Chemotherapy regimen, donor source and conditioning regimen before allo-HSCT were not prescribed in the present study. Secondary objectives were the comparison of overall survival (OS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) between the groups. In the chemotherapy group, we extracted risk factors for relapse. We also divided the patients into groups that received a pediatric-inspired regimen alone and followed by allo-HSCT (pediatric regimen) or conventional regimen for adults alone and followed by allo-HSCT (adult regimen) to evaluate whether the pediatric regimen improved outcome (14) (15) (16) (17) . The protocol was reviewed and approved by the institutional review board of each participating center and was conducted in accordance with the Declaration of Helsinki. This study is registered at http:// www.umin.ac.jp/ctr/ as # C000016287.
Definitions
EFS was measured from the date of diagnosis until relapse or death from any cause, with observations censored at the date of last contact for patients without relapse. OS was measured from the date of diagnosis until death from any cause, with observations censored at the date of last contact. NRM was defined as death for any reason other than relapse. CR was defined as <5% morphologically identified blasts in bone marrow specimens, provided the patient had a peripheral blood neutrophil count >1000/μl, platelet count >100 000/μl, and no evidence of extramedullary disease. Immunophenotyping was performed using flow cytometry with CD45 gating of the blast population, and positivity was defined as expression in >20% of blasts. We used the classifications of cytogenetic risk defined by the Southwest Oncology Group (SWOG) 9400 study. High-risk karyotype was defined as one of the following cytogenetic factors: t(4;11) MLL translocation, t(8;14), complex karyotype (≥5 chromosomal abnormalities), low hypodiploidy (30-39 chromosomes), or near triploidy (60-78 chromosomes) (18) . The pediatric regimen was defined as any multi-drug combination chemotherapy including intensified doses of nonmyelotoxic drugs, such as Lasparaginase, vincristine and steroids, compared with the conventional chemotherapy for adults (10) . The outcomes were updated as of October 2015.
Statistical analyses
Differences in patient characteristics between the allo-HSCT and chemotherapy groups were analyzed using Fisher's exact test or Student's t-test. The EFS and OS were calculated using the KaplanMeier method and compared using the log-rank test if they did not include the evaluation of HSCT. In any evaluation of HSCT, direct comparison of EFS and OS from entry are biased in favor of HSCT group because patients die before HSCT are counted in chemotherapy group. To reduce the bias, we used Mantel-Byar Method and Simon and Makuch plot, in which HSCT was a time-dependent covariate. The CIR was calculated using Gray's method considering NRM as a competing risk factor. Risk factors for relapse were analyzed using the Cox proportional hazards model. In multivariate analysis, factors were adjusted using the Cox proportional hazards model, and a stepwise backward procedure was used to construct a set of independent predictors. All tests were two-sided, with P values ≤ 0.05 considered statistically significant. All statistical analyses 
Continued were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 1.6-3) (19) .
Results
Chemotherapy versus allo-HSCT
We retrospectively analyzed 96 Ph-negative ALL patients treated by allo-HSCT following chemotherapy (HSCT group, N = 34) or chemotherapy alone (chemotherapy group, N = 62) in 1CR. Patient characteristics are shown in Table 1 . The chemotherapy group was significantly older and exhibited higher CD20 positivity than the HSCT group; however, other characteristics were not significantly different. In the HSCT group, 10 patients received the pediatric regimen and 24 received the adult regimen before allo-HSCT. In the chemotherapy group, 11 patients received the pediatric regimen and 51 received the adult regimen. No significant difference in EFS or OS at 3 years was observed between the HSCT and chemotherapy groups (EFS: 67% vs. 54%, P = 0.367, Fig. 1A ; OS: 72% vs. 69%, P = 0.712, Fig. 1B) . The CIR at 3 years was significantly lower in the HSCT group than the chemotherapy group (27% vs. 46%, P = 0.032, Fig. 1C ). There was no significant difference in NRM at 3 years between the two groups (6% vs. 3%, P = 0.250, Fig. 1D ).
In the HSCT group, we could not find any significant risk factors in univariate and multivariate analysis; White blood cell (WBC) count, cytogenetic abnormalities, donor sources, and conditioning regimen were not associated with EFS. In the chemotherapy group, however, the adult regimen, high WBC count (≥30 000/μl), low platelet count (<50 000/μl), and CD20 positivity were associated with poorer EFS by univariate analysis. In multivariate analysis, the adult regimen, high WBC count, and CD20 positivity were significantly associated with poor EFS (Table 2) . Of note, EFS and OS at 3 years were significantly higher in patients receiving the pediatric regimen compared with those receiving the adult regimen in the chemotherapy group (EFS: 91% vs. 43%, P = 0.007, Supplemental Fig. 1A ; OS: 86% vs. 61%, P = 0.032, Supplemental Fig. 1B) , although background characteristics did not differ between the two groups except for lower median age in the pediatric regimen group (20 years vs. 54 years, P < 0.001). Since the chemotherapy regimen had a significant influence on outcome, we performed further analyses according to the chemotherapy regimen.
Impact of allo-HSCT on survival among patients treated with the pediatric or adult regimen
We compared the survival of patients who received the pediatric regimen alone to those receiving the pediatric regimen followed by allo-HSCT. Background characteristics were not significantly different between these groups (Supplemental Table 1 ). Induction failure was the only significant risk factor for poor EFS in univariate and multivariate analysis (Supplemental Table 1 ). There were no differences in survival rates between the patients receiving pediatric chemotherapy alone and followed by allo-HSCT (EFS: 92% vs. 70%, P = 0.206, Supplemental Fig. 2A ; OS: 100% vs. 60%, P = 0.109, Supplemental Fig. 2B) .
Next, we compared the survival of patients who received the adult regimen alone to those receiving the adult regimen followed by allo-HSCT. The patients who received HSCT were significantly younger than those receiving adult chemotherapy alone, but the HSCT, hematopoietic stem cell transplantation; WBC, white blood cell; CNS, central nerve system; JALSG, Japan Adult Leukemia Study Group; GRAALL, Group for Research on Adult Acute Lymphoblastic Leukemia; R-BM, related bone marrow; U-BM, unrelated bone marrow; R-PBSC, related peripheral blood stem cell; U-PBSC, unrelated peripheral blood stem cell; CB, cord blood; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; TBI, total body irradiation; CY, cyclophosphamide; CA, cytarabine; Flu, fludarabine; Mel, melphalan; CsA, cyclosporin A; MTX, methotrexate; GVHD, graft versus host disease.
other characteristics did not differ (Supplemental Table 3 ). Treatment with allo-HSCT did not improve EFS (Supplemental Table 4 ). Survival curves for the patients receiving adult chemotherapy alone and followed by allo-HSCT are shown in Supplemental 
Risk factors in patients treated with the adult regimen
We analyzed patients treated with the adult-type chemotherapy regimen alone to extract characteristic indicative of patients who should have received allo-HSCT in 1CR. CD20 positivity was the only significant risk factor in univariate analysis, and CD20 positivity and high WBC count (≥30 000/μl) were significantly associated with poor EFS in multivariate analysis (Table 3) . Patients with one or more of these risk factors had worse EFS at 3 years compared with patients with no risk factors (22% vs. 75%, P = 0.001, Fig. 2A ). In patients with one or more of these risk factors, EFS at 3 years was significantly lower in patients who received the adult regimen alone compared with patients who received the adult regimen followed by allo-HSCT (24% vs. 77%, P = 0.006, Fig. 2B ). In patients with no risk factors, EFS at 3 years was comparable between the patients who received the adult regimen alone and those who received the adult regimen followed by allo-HSCT (76% vs. 50%, P = 0.463, Fig. 2C ). Among patients who received the adult regimen followed by allo-HSCT, these risk factors were not associated with poor EFS (P = 0.352, data not shown).
Discussion
We retrospectively analyzed the long-term follow-ups of 96 adult Ph-negative ALL patients who achieved 1CR and compared treatment outcomes between the HSCT and chemotherapy groups. No significant differences in EFS or OS were observed between these two groups; however, CIR was significantly higher in the chemotherapy group than in the HSCT group. Adult regimen, high WBC count (≥30 000/μl), and CD20 positivity were found to be significantly associated with poor EFS in the chemotherapy group. Several recent studies have reported favorable outcomes with the use of pediatric-inspired regimens in adolescents and young adults (9, 10) , with survival benefits as good as those with the use of allo-HSCT (12, 13) . Indeed, we did not find allo-HSCT to be superior to chemotherapy in patients who received the pediatric regimen, whether high or low risk. Thus, patients achieving 1CR who can tolerate the pediatric regimen may not require or benefit from allo-HSCT. Beldjord et al. reported that high-risk cytogenetics and post-induction high minimal residual disease level were associated with relapse in adult ALL patients treated with pediatric-inspired chemotherapy (20) ; thus, allo-HSCT after 1CR should be considered in these high-risk patients. Although the pediatric-inspired regimen was associated with favorable outcomes in the present study, treatment with the pediatric regimen is clinically challenging in older patients. Storring et al. reported that patients older than 35 years had lower OS and were less likely to achieve 80% of the targeted L-asparaginase dosing during intensification (9) . They suggested that the older patients are not sufficiently tolerant to maintain the dose intensity, leading to poor outcome. A recent meta-analysis concluded that allo-HSCT from matched sibling donors does not improve survival in Ph-negative ALL patients ≥35 years old (8) , so identifying the optimal candidates for allo-HSCT in 1CR from those ineligible for the pediatric regimen is necessary to improve the survival of adult ALL patients.
WBC count is a well-known risk factor in ALL patients, and WBC count >30 000/μl is associated with a high risk for adverse events (21) . Additionally, two retrospective analyses reported that CD20 positivity was associated with adverse outcomes, including higher CIR and decreased survival (22, 23) . In the present study, high WBC count and CD20-positive status were associated with decreased EFS in patients receiving the adult chemotherapy regimen, and subsequent allo-HSCT was demonstrated to improve their treatment outcomes. On the other hand, these factors were not associated with EFS in the pediatric chemotherapy group and patients who received the adult regimen followed by allo-HSCT, which indicates that these risk factors can be overcome by these intensive treatments. Therefore, patients ineligible for the pediatric regimen with high WBC count and/or CD20 expression may achieve the greatest benefit from allo-HSCT in 1CR.
Treatment modification using the CD20 monoclonal antibody rituximab has been explored in CD20-positive patients. Hyper-CVAD plus rituximab was reported to significantly improve CR duration and OS in newly diagnosed Ph-negative ALL patients compared with a standard hyper-CVAD regimen without rituximab (24) . However, the efficacy of rituximab could not be evaluated in the present study, as few patients received rituximab therapy due to regulation of the medical insurance system in Japan.
Multiple cytogenetic abnormalities have also been reported as risk factors for adverse events in ALL patients. In the MRC UKALLXII/ECOG 2993 trial, t(4;11) MLL translocation, t(8;14), complex karyotype, low hypodiploidy and near triploidy were significantly associated with decreased OS and EFS in Ph-negative ALL patients (25) . In the SWOG 9400 study, cytogenetics was a significant independent predictor of outcome in multivariate analysis, whereas age and WBC count lost prognostic significance (18) . The SWOG 9400 study further reported that high-risk karyotypes defined in the MRC/ECOG 2993 trial were associated with low RFS and OS (18) . In the present study, we were unable to identify an Comparison of EFS based on risk stratification among patients who received the adult regimen. EFS between risk group and no risk group (A), EFS between chemotherapy alone and followed by allo-HSCT in risk group (B), EFS between chemotherapy alone and followed by allo-HSCT in no risk group (C).
association between cytogenetic abnormalities and survival as only 19 patients (20%) had high-risk karyotypes. There are several limitations to the present study. Due to the small cohort size with a long-term follow-up and the retrospective study design, substantial variation was observed in patient characteristics, including age and treatment protocols. Furthermore, the HSCT group may have included a greater proportion of patients with poorer prognosis than the chemotherapy group, although we observed no significant differences between the two groups except for patient age.
In conclusion, outcomes in Ph-negative ALL patients who received a pediatric-inspired chemotherapy regimen were equivalent to those receiving additional allo-HSCT. Outcomes of patients who received an adult regimen were poor, but were improved by additional allo-HSCT. As survival was especially poor in patients with high WBC count and/or CD20 positivity, these patients may benefit most from allo-HSCT in 1CR. The decision to perform allo-HSCT in patients without an HLA-matched donor is clinically challenging. We believe the findings of the present study will help in such decisions.
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